Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon beta-1a Nebuliser 48 μg/mL · 1 trial · 1 indication
Evaluation of the efficacy of inhaled AZD9412 compared to placebo in preventing severe exacerbations during the 14 day treatment phase following the onset of an URTI in asthmatic patients. A severe exacerbation was defined as worsening asthma symptoms and 1. use of systemic corticosteroids (or a temporary increase of at least 2-fold in a stable oral corticosteroid background dose) for at least 3 consecutive days and/or 2. an unscheduled visit or emergency room visit due to asthma symptoms that required at least 1 dose of systemic corticosteroids and/or 3. an in-patient hospitalisation due to asthma requiring at least 1 dose of systemic corticosteroids. The number of patients with severe asthma exacerbations with onset during the treatment phase is presented for each treatment group.
| Arm | Type | Description |
|---|---|---|
| Placebo (matching) | PLACEBO_COMPARATOR | Placebo, once daily inhalation for 14 days |
| Interferon beta-1a | EXPERIMENTAL | Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a Nebuliser solution 48 μg/mL | DRUG | Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days |
| Placebo | DRUG | Placebo solution for once daily inhalation for 14 days |
Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria: 1. Provision of signed and dated written informed consent prior to any study specific procedures 2. Male or female aged 18 and above at the time of enrolment 3. History of physician-diagnosed asthma requi...
Interferon beta-1a Nebuliser 48 μg/mL is an investigational drug being studied for the treatment of asthma. It is administered via nebulisation and is intended for use after the onset of symptoms of an upper respiratory tract infection in asthma patients. The drug is currently in Phase 2 clinical development.
Interferon beta-1a Nebuliser 48 μg/mL is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the efficacy, safety, and tolerability of this investigational treatment for asthma.
Interferon beta-1a Nebuliser 48 μg/mL is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is being studied for its potential use in treating asthma patients.
Interferon beta-1a Nebuliser 48 μg/mL is associated with one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT02491684. This trial evaluated the efficacy, safety, and tolerability of 14 days of once-daily inhaled interferon beta-1a after the onset of upper respiratory tract infection symptoms in asthma patients.
Interferon beta-1a Nebuliser 48 μg/mL is a specific formulation of interferon beta-1a, delivered via nebulisation at a concentration of 48 μg/mL. It is being studied as an inhaled treatment for asthma, whereas other forms of interferon beta-1a may be used for different indications or administered by other routes.